Pharma / Biotech

Tissue distribution of 35S-metabolically labeled neublastin (BG00010) in rats.

Related Articles

Tissue distribution of 35S-metabolically labeled neublastin (BG00010) in rats.

J Pharm Biomed Anal. 2020 Feb 06;184:113154

Authors: Penner N, Purushothama S, Pepinsky B

Neublastin (NBN) is a neurotrophic growth factor that promotes the survival and regenerative properties of nociceptive neurons and has been tested in clinical trials as a treatment for neuropathic pain in individuals with sciatica and painful lumbosacral radiculopathy. Like many low molecular weight heparin binding proteins, NBN is rapidly cleared from the blood following systemic administration. To explore ADME properties of NBN in rats, we used metabolically 35S-labeled NBN following IV and SC administration quantifying counts and intact protein in kidney, liver, brain, serum, and urine at 5 min, 8 h, 24 h and 48 h, and biodistribution in whole body carcasses by QWBA at 2, 8, 48, 96, and 168 h post dose. NBN is rapidly taken up by tissues mainly by liver and kidney and then degraded. Products of degradation are excreted in urine or recycled and utilized for resynthesis. The data we generated for NBN provides a first look at the complex clearance mechanisms for this protein and should aid in the design of ADME studies for other heparin binding proteins.

PMID: 32097771 [PubMed – as supplied by publisher]

Source link

Related posts

ONDANSETRON Tablet, Orally Disintegrating [Proficient Rx LP]


Zerbaxa ASPECT-NP Trial Demonstrated Noninferiority to Meropenem for Ventilated Nosocomial Pneumonia


Prediction Models for Voriconazole Pharmacokinetics Based on Pharmacogenetics: An Exploratory Study in Spanish population.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World